Centum S&P Global Ratings has revised its outlook on Biocon Biologics Limited, moving the company to a Positive CreditWatch in recognition of its rapid progress in lowering debt. On December 10, 2025, the agency affirmed its ‘BB’ long-term issuer rating and the ‘BB’ rating on the company’s senior secured notes, while shifting the outlook to Positive.
The change reflects confidence that Biocon Biologics is taking meaningful steps toward strengthening its balance sheet. The announcement follows Biocon Limited’s decision to take full ownership of its biosimilars subsidiary by acquiring the roughly 25% held by minority shareholders through an equity-swap arrangement.
Under this restructuring plan, Biocon will convert the compulsorily convertible preference shares (CCPS) held by Viatris Inc into a mix of cash and equity. The company intends to fund the cash portion—estimated at about INR 45 billion—entirely through fresh equity issuance.
S&P Global highlighted that these actions will significantly cut Biocon’s consolidated debt by March 2026, particularly because instruments previously considered debt-like, including CCPS and securities with put options, will be removed from its capital mix. With repayments already made on various debentures earlier in the year, the company’s future borrowings are expected to consist mainly of senior secured notes, bilateral loans, and working capital financing. S&P projects that Biocon’s adjusted debt will drop from INR 248 billion in March 2025 to around INR 120 billion by March 2026.
Biocon Biologics, a subsidiary of Biocon Limited, operates as a fully integrated global biosimilars manufacturer, focused on making advanced biologics more accessible worldwide. The company delivers affordable, high-quality therapies to more than 6.3 million patients across over 120 countries, supported by large-scale manufacturing, advanced scientific platforms, and strong quality systems. Its portfolio includes 10 commercialized biosimilars across major markets such as the US, Europe, Australia, Canada, and Japan, along with a robust pipeline of more than 20 candidates targeting diseases in oncology, immunology, diabetes care, ophthalmology, and more.
Biocon Limited, listed since 2004, continues to position itself as a global leader in biopharmaceutical innovation. Its focus spans novel biologics, biosimilars, complex APIs, and generic formulations distributed across multiple continents. The company is also advancing a promising immunotherapy pipeline. Guided by strong ESG commitments, the Biocon group aims to expand access to complex therapies while contributing to broader sustainability goals.